Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash & Equivalents (2020 - 2025)

Maxcyte (MXCT) has disclosed Cash & Equivalents for 6 consecutive years, with $13.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 64.9% to $13.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.0 million, a 64.9% decrease, with the full-year FY2024 number at $27.9 million, down 40.04% from a year prior.
  • Cash & Equivalents was $13.0 million for Q3 2025 at Maxcyte, down from $15.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $239.8 million in Q1 2022 to a low of $11.1 million in Q4 2022.
  • A 5-year average of $50.6 million and a median of $37.7 million in 2023 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 320.3% in 2023; the steepest drop was 84.22% in 2023.
  • Maxcyte's Cash & Equivalents stood at $47.8 million in 2021, then crashed by 76.84% to $11.1 million in 2022, then soared by 320.3% to $46.5 million in 2023, then plummeted by 40.04% to $27.9 million in 2024, then tumbled by 53.48% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cash & Equivalents are $13.0 million (Q3 2025), $15.2 million (Q2 2025), and $23.4 million (Q1 2025).